BridgeMD
Nordic Pancreatic Cancer Trial (NORPACT) – 1
EU CTIS ID: 2024-517719-65-00
What this study is testing
The aim of this study is to assess the additional value of neoadjuvant chemotherapy to the standard treatment (surgery + adjuvant chemotherapy) for resectable cancer of the pancreatic head as a means of avoiding early mortality and improve overall survival.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Resectable tumour of the pancreatic head radiologically strongly suspect of pancreatic adenocarcinoma
- T1-3, Nx, M0 (UICC 7th version, 2010)
- Age > 18 year and considered fit for major surgery
- Written informed consent
- Considered able to receive the study specific chemotherapy
You likely can't join if
- Co-morbidity precluding pancreatoduodenectomy
- Mental or organic disorders which could interfere with informed consent or treatments
- Other malignancy within the past 5 years, except non-melanomatous skin or non-invasive cervical cancer
- Percutaneous tumor biopsy
- Any reason why, in the opinion of the investigator, the patient should not participate
- Sensitivity to any of the study medications or any of the ingredients or excipients of these medications
See the full eligibility criteria
- Resectable tumour of the pancreatic head radiologically strongly suspect of pancreatic adenocarcinoma
- T1-3, Nx, M0 (UICC 7th version, 2010)
- Age > 18 year and considered fit for major surgery
- Written informed consent
- Considered able to receive the study specific chemotherapy
- Co-morbidity precluding pancreatoduodenectomy
- Mental or organic disorders which could interfere with informed consent or treatments
- Other malignancy within the past 5 years, except non-melanomatous skin or non-invasive cervical cancer
- Percutaneous tumor biopsy
- Any reason why, in the opinion of the investigator, the patient should not participate
- Sensitivity to any of the study medications or any of the ingredients or excipients of these medications
- Chronic neuropathy ≥ grade 2
- WHO performance score ≥ 2
- Granulocyte count < 1500 per cubic millimetre (< 1,5 x 109/L)
- Platelet count < 100 000 per cubic millimetre (< 100 x 109/L)
- Serum creatinine > 1.5 UNL (upper limit normal range)
- Albumin < 2,5 g/dl (< 25 g/L)
- Female patients in child bearing age not using adequate contraception, pregnant or lactating women
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.